Back to RVTY
RVTY: Q3 Beat, Growth vs. Rich Valuation
$RVTYNEUTRALHealthcare

RVTY: Q3 Beat, Growth vs. Rich Valuation

Revvity (RVTY) beat Q3 estimates and raised its 2026 view on Life Sciences strength, yet the stock trades at a premium versus forward metrics and carries limited analyst upside. This report reviews fundamentals, valuation, and the key catalysts and risks retail investors should monitor.

November 8, 202611 min read
Current Price
$155.11
+2.84%
Analyst Rating
Hold
Price Target
$140.00
-9.7% upside
P/E Ratio
68.63

Executive Summary

Investment Thesis: Revvity reported a Q3 2026 earnings beat and raised its 2026 outlook after Life Sciences and Diagnostics strength. Operational momentum and margin expansion are supporting cash flow, while a manageable balance sheet preserves optionality for M&A and product investment. At the same time, trailing multiples remain elevated and the implied analyst mean target sits below the current price, signaling a mixed risk/reward profile.

Current Price: $155.11 as of Friday, November 6 | Key Metric: Forward P/E ~26.0 | Stance: NEUTRAL

Company Overview

Revvity, Inc. ($RVTY) is a healthcare technology company focused on diagnostic, life-science, and genomic solutions. The company supplies instruments, consumables and services that support research, diagnostics, and drug development workflows.

Key Products & Competitive Position

  • Core Business: Life Sciences tools and Diagnostics platforms that service pharmaceutical, academic, and clinical customers.
  • Key Products: Laboratory instruments, assay kits, diagnostic reagents, workflow software, and associated services.
  • Competitive Moat: Broad product portfolio across adjacent markets, long-term service contracts, and installed-base economics that drive recurring revenue.

Recent Developments

Q3 2026 results exceeded estimates, led by stronger demand in the Life Sciences segment and continued Diagnostics growth. Management lifted the 2026 view following margin expansion. Zacks upgraded the stock to a Rank #2 (Buy) on November 6, 2026, reflecting increased optimism among some analysts. Fund-level ownership moves, such as activity by the Madison Mid Cap Fund, have been noted in recent filings.

Financial Snapshot

Market Cap$17.31B
P/E Ratio68.63 (Trailing)
52-Week Range$81.22 - $171.74
Dividend Yield0.18%
EPS (TTM)$2.27
ROE3.50%

Revenue & Earnings Trends

Revvity reported total revenue around $2.94B (latest reported), with revenue growth reported at roughly 4.3% in recent data and earnings growth materially higher at about 37.8% year over year. Q3 2026 produced an EPS of $1.38 versus estimates of $1.30, reflecting margin leverage from higher mix in higher-margin Life Sciences sales.

Balance Sheet Highlights

The company carries roughly $593M in cash against about $2.77B in total debt, yielding a net-debt position but manageable leverage versus EBITDA. The current ratio is strong at 2.65 and the quick ratio is healthy at about 1.83, indicating short-term liquidity headroom. Operating cash flow and free cash flow are positive, supporting reinvestment and potential capital allocation options.

Valuation Analysis

Current Valuation Metrics

Forward P/E~26.0vs Industry: mid-20s
PEG Ratio~1.8Growth-adjusted
EV/EBITDA~21.8vs Historical: elevated
P/S Ratio~5.9vs Peers: premium

Historical Comparison

Trailing P/E sits high at about 68.6 driven by a lower trailing EPS base and recent share appreciation. On a forward basis the multiple falls materially to roughly 26, which better reflects analyst growth expectations. Still, EV/EBITDA and P/S suggest Revvity trades at a premium to many mid-cap healthcare peers, driven by growth and margin expectations.

Fair Value Estimate

Combining forward multiples, recent guidance revisions, and a simple discounted cash-flow sensitivity, a fair value range for $RVTY centered on $130 to $150 per share is reasonable under base-case growth assumptions. The analyst mean target of $140 aligns with the midpoint of that range, which implies limited upside from the last close of $155.11 as of Friday, November 6.

Competitive Landscape

Market Position

Market Share: Mid single-digit to low double-digit in core life-science and diagnostic niches | Ranking: #3-5 among select instrument and diagnostics suppliers in many served segments

Key Competitors

Thermo Fisher Scientific (TMO)Thermo Fisher Scientific, a larger diversified lab tools and diagnostics provider
Danaher (DHR)Danaher, diversified life sciences and diagnostics equipment and consumables
Intuitive Surgical (ISRG)Intuitive Surgical, representative of higher-margin medtech peers though in a different specialty

Competitive Advantages

  • Moat 1: Installed base and recurring consumables revenue that smooths sales cycles.
  • Moat 2: Diversified revenue streams across research, diagnostics and services, reducing single-market exposure.
  • Moat 3: Ongoing product innovation and a services footprint that enhance switching costs for customers.

Earnings Track Record

Last 4 Quarters: 3 beats / 1 miss

Recent Earnings History

Q3 2026$1.38 vs $1.30 estBEAT
Q2 2026Reported with margin improvementBEAT
Q1 2026Mixed results, near estimatesMISS
Q4 2025Solid execution, revenue growthBEAT

Guidance Trend

Management raised its 2026 view following Q3, pointing to stronger demand in Life Sciences and expanding interest across Diagnostics. Analysts revised forward estimates higher in the immediate aftermath. The December quarter and the February 1, 2027 earnings release will be watched for confirmation of sustained margin progression.

Analyst Sentiment

Consensus Rating: Hold

Strong Buy: 0 Buy: 6 Hold: 11 Sell: 0 Strong Sell: 1

Price Targets

  • Low: $115
  • Mean: $140 (-9.7% downside vs $155.11)
  • High: $165

Recent Analyst Actions

Zacks upgraded $RVTY to a Rank #2 (Buy) on November 6 following the Q3 beat and raised view. Other coverage remains mixed with several holds and a handful of buys. The consensus remains neutral, reflecting a split between optimism on execution and concerns about the premium multiple versus slower-turning diagnostics peers.

Recent News & Catalysts

Key Developments

  • Zacks Upgrade (11/6/2026): Zacks moved Revvity to a Rank #2 on improved earnings prospects after Q3.
  • Q3 2026 Earnings Beat (11/3/2026): EPS $1.38 vs $1.30 est, company cited Life Sciences strength and margin expansion, with an upward revision to 2026 guidance.
  • Fund Activity (11/6/2026): Madison Mid Cap Fund reported portfolio activity with Revvity mentioned among holdings, reflecting institutional interest among mid-cap funds.

Upcoming Catalysts

Next Earnings: Expected 2027-02-01 | Key Events: Full-year guidance clarity, margin outlook, commentary on Life Sciences demand trajectory and diagnostic backlog trends

Technical Outlook

Current Price: $155.11 vs 52-Week High: $171.74 (-9.7% from high)

Trend Analysis

The stock has outperformed over the last 6 to 12 months, with year-to-date returns above 60% and notable momentum coming into Q3 results. The recent beat and guidance lift triggered a short-term uptick. On the other hand, the move leaves the stock trading below its 52-week high and above many intermediate moving averages, so volatility may increase around earnings and guidance updates.

Key Levels

  • Resistance: $171.74 (52-week high), $180 - psychological level
  • Support: $150 (recent close area), $135 (analyst median zone), $115 (analyst low)

Bull vs Bear Case

Bull Case

  • Catalyst 1: Continued Life Sciences demand drives above-consensus revenue and margin expansion.
  • Catalyst 2: Operational improvements and cross-selling raise recurring revenue and cash conversion.
  • Catalyst 3: Multiple compression reverses as growth proves sustainable, narrowing the gap with larger peers.

Bull Target: $165 (+6% vs $155.11)

Bear Case

  • Risk 1: High trailing valuation creates downside if growth moderates or guidance disappoints.
  • Risk 2: Diagnostic demand could be cyclical, exposing revenue to headwinds if end-market spending slows.
  • Risk 3: Competitive pressure from larger incumbents could pressure pricing and margins, limiting market share gains.

Bear Target: $115 (-26% vs $155.11)

Risks to Consider

  • Valuation Risk: Trailing P/E is elevated and EV/EBITDA sits above many peers. If execution slips, multiples could re-rate lower quickly.
  • Competitive Risk: Larger diversified players like $TMO and $DHR have scale advantages and R&D budgets that could blunt Revvity's growth in certain segments.
  • Macro Risk: Capital spending patterns at pharma, biotech and clinical labs are sensitive to macro and funding cycles, which could slow equipment and consumable purchases.
  • Execution Risk: Maintaining margin expansion requires continued product mix improvement and tight cost control; any reversal could pressure EPS.

Bottom Line

Investment Verdict: NEUTRAL

Revvity shows operational momentum, evidenced by a Q3 2026 beat and an upgraded annual view driven by Life Sciences and Diagnostics. Those operational positives are balanced by a premium trailing multiple and analyst targets that on average sit below the recent close. Analysts and market participants will likely look to the February 1, 2027 earnings release for confirmation that margin gains are sustainable and revenue growth is durable.

Action Items for Investors

  • Long-term investors: Monitor sustained margin and revenue trends and reassess valuation relative to peer multiples before changing exposure. Consider whether the company’s execution aligns with the premium valuation level.
  • Short-term traders: Watch price reaction to upcoming guidance and near-term macro headlines, as these can drive sharp moves around reported results and estimate revisions.
  • Risk management: Track debt leverage and cash flow conversion. Set exposure limits and consider position sizing given the stock’s volatility and premium multiples.

What to Watch This Week

  • Analyst notes and revisions following the Zacks upgrade and Q3 commentary.
  • Volume and price action heading into the long weekend, given the last trade data is as of Friday, November 6.
  • Corporate disclosures and any pre-earnings commentary ahead of the expected 2027-02-01 report.

Can Revvity sustain the higher margins and revenue mix that justified the Q3 uplift? And will those operational gains be enough to support current multiples if macro or competitive headwinds intensify? Analysts and market participants will likely answer those questions over the next two quarters.

Share this report

Share this article

Spread the word on social media

Think RVTY will outperform? Prove it.

Free practice contests — earn Alpha Coins
Enter a Contest

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.

Spotted something wrong? Report an error.